Generalized Linear Porokeratosis in a Child: Case Study

Background. Linear porokeratosis is a rare type of poroceratosis, genetically determined disorder of mevalonate pathway in keratinocytes. It is characterized by high risk of malignant neoplasms (squamous cell carcinoma, basal cell carcinoma, Bowen's disease, melanoma). There is no pathogenetic treatment. Case description. Patient K., 8 years old, had rashes from the first days of life. The rashes have spread all over the body with age. Positive effect in partial regression of rashes was noted after 3 months on acitretin administration at dosage of 10 mg/day. Conclusion. The positive effect of linear porokeratosis management via acitretin has been shown. However, the definition of standard treatment regimens for porokeratosis remains relevant.

1. Saleva-Stateva M, Hess M, Technau-Hafsi K, et al. Molecular characterization and natural history of linear porokeratosis: A case series. J Am Acad Dermatol. 2021;85(6):1603–1606. doi: https://doi.org/10.1016/j.jaad.2020.11.061

2. Yang J, Du YQ, Fang XY, et al. Linear porokeratosis of the foot with dermoscopic manifestations: A case report. World J Clin Cases. 2022;10(31):11585–11589. doi: https://doi.org/10.12998/wjcc.v10.i31.11585

3. Vargas-Mora P, Morgado-Carrasco D, Fustà-Novell X. Porokeratosis: A Review of Its Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment. Actas Dermosifiliogr (Engl Ed). 2020;111(7):545–560. doi: https://doi.org/10.1016/j.ad.2020.03.005

4. Pietkiewicz P, Korecka K, Salwowska N, et al. Porokeratoses — A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants. Metabolites. 2023;13(12):1176. doi: https://doi.org/10.3390/metabo13121176

5. Yadav P, Sanke S, Mendiratta V, Chander R. Generalized Linear Porokeratosis in a Bilateral Distribution: An Unusual Presentation. Skinmed. 2022;20(3):220–223.

6. Atzmony L, Khan HM, Lim YH, et al. Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatol. 2019;155(5):548–555. doi: https://doi.org/10.1001/jamadermatol.2019.0016

7. Ansari F, Mudugal R, Singh S, et al. Hystrix-like linear porokeratosis: a clinicopathological challenge. Int J Dermatol. 2022;61(2):e76–e79. doi: https://doi.org/10.1111/ijd.15711

8. Zhang Z, Li C, Wu F, et al. Genomic variations of the mevalonate pathway in porokeratosis. Elife. 2015;4:e06322. doi: https://doi.org/10.7554/eLife.06322

9. Touitou I. Twists and turns of the genetic story of mevalonate kinase-associated diseases: A review. Genes Dis. 2021;9(4): 1000–1007. doi: https://doi.org/10.1016/j.gendis.2021.05.002

10. Kostopoulos-Kanitakis KA, Kanitakis J. Porokeratoses: an update on pathogenesis and treatment. Int J Dermatol. 2025;64(1):62–71. doi: https://doi.org/10.1111/ijd.17411

11. Tappel AC, Tiwari N, Zlotoff B. Linear porokeratosis associated with Bardet-Biedl syndrome: A case report. Pediatr Dermatol. 2019;36(3):346–348. doi: https://doi.org/10.1111/pde.13776

12. Anderska A, Kaczmarska-Such A, Mazur E, Reich A. Porokeratoses-A Rare Group of Dermatoses. Medicina (Kaunas). 2024;60(11):1876. doi: https://doi.org/10.3390/medicina60111876

13. Lu JD, Mufti A, Sachdeva M, et al. Drugs associated with development of porokeratosis: A systematic review. Dermatol Ther. 2021;34(1):e14560. doi: https://doi.org/10.1111/dth.14560

14. Novice T, Nakamura M, Helfrich Y. The Malignancy Potential of Porokeratosis: A Single-Center Retrospective Study. Cureus. 2021;13(2):e13083. doi: https://doi.org/10.7759/cureus.13083

15. Williams GM, Dreyer MA, Fillman EP. Porokeratosis. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.

16. Inci R, Zagoras T, Kantere D, et al. Porokeratosis is one of the most common genodermatoses and is associated with an increased risk of keratinocyte cancer and melanoma. J Eur Acad Dermatol Venereol. 2023;37(2):420–427. doi: https://doi.org/10.1111/jdv.18587

17. Shirahatti T, Bangaru H, Sathish S. A Clinico-Epidemiological Study on Porokeratosis. Indian J Dermatol. 2024;69(4):365. doi: https://doi.org/10.4103/ijd.ijd_131_24

18. Zaar O, Polesie S, Navarrete-Dechent C, et al. Dermoscopy of porokeratosis: results from a multicentre study of the International Dermoscopy Society. J Eur Acad Dermatol Venereol. 2021;35(10):2091–2096. doi: https://doi.org/10.1111/jdv.17439

19. Noble CA, Bhate C, Duong BT, et al. Clinical-pathologic correlation: The impact of grossing at the bedside. Semin Diagn Pathol. 2025;42(2):150836. doi: https://doi.org/10.1053/j.semdp.2024.01.007

20. Atzmony L, Ugwu N, Hamilton C, et al. Inflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders. Pediatr Dermatol. 2022;39(6): 903–907. doi: https://doi.org/10.1111/pde.15094

21. Shiiya C, Aoki S, Nakabayashi K, et al. Linear and disseminated porokeratosis in one family showing identical and independent second hits in MVD among skin lesions, respectively: a proofof-concept study. Br J Dermatol. 2021;184(6):1209–1212. doi: https://doi.org/10.1111/bjd.19824

22. Zhang W, Nie X, Shi L, et al. A Novel PMVK Variant Associated with Familial Porokeratosis. Hum Hered. 2023;88(1):50–57. doi: https://doi.org/10.1159/000531120

23. Kubo A, Sasaki T, Suzuki H, et al. Clonal Expansion of SecondHit Cells with Somatic Recombinations or C>T Transitions Form Porokeratosis in MVD or MVK Mutant Heterozygotes. J Invest Dermatol. 2019;139(12):2458–2466.e9. doi: https://doi.org/10.1016/j.jid.2019.05.020

24. Weidner T, Illing T, Miguel D, Elsner P. Treatment of Porokeratosis: A Systematic Review. Am J Clin Dermatol. 2017;18(4):435–449. doi: https://doi.org/10.1007/s40257-017-0271-3

25. Murashkin N.N., Ambarchian E.T., Epishev R.V., Materikin A.I., Opryatin L.A., Ivanov R.A., Kukoleva D.S. Photodermatoses in Childhood. Current Pediatrics. 2021;20(5):360–369. (In Russ.) https://doi.org/10.15690/vsp.v20i5.2308.

26. Abbott-Frey AM, Coromilas AJ, Niedt GW, Lewin JM. Recurrent Squamous Cell Carcinoma Arising Within a Linear Porokeratosis. J Drugs Dermatol. 2020;19(2):205–206. doi: https://doi.org/10.36849/JDD.2020.4640.